Inaxaplin

The FDA is expected to decide on the approval of suzetrigine for acute pain treatment by January 30, potentially expanding Vertex's market beyond cystic fibrosis.

The FDA has approved JOURNAVX™ (suzetrigine) as a first-in-class, non-opioid treatment for moderate-to-severe acute pain in adults.

Vertex Pharmaceuticals increased its full-year product revenue guidance to $10.8 billion to $10.9 billion, driven by strong performance in CF and the early launch of CASGEVY.

Vertex presented data on povetacicept in IgA nephropathy, showing a 66% reduction in UPCR at 48 weeks and stable renal function.

A clinical trial of inaxaplin, a novel drug targeting the APOL1 protein, demonstrated a significant reduction in protein leakage in the urine of patients with serious kidney disease.